Saturday 17 October 2026 Export CLLS’s income statement to Excel — free account

Cellectis S.A.

Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.

1.04 0.07 −6.31%

Follow CLLS

Alert me

Market cap: $79.9M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 2/9
Altman Z: −0.03
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 30.97%

Capital & Financial Ratios $m

Market Cap 79.92

Revenue 63.82

Net Income (65.31)

Free Cash Flow (43.80)

Net Debt (93.16)

Current Ratio 1.37

Debt/Equity 1.79

P/E ratio 0.00

Fwd P/E —

P/S ratio 1.64

P/B ratio 2.55

Past 5Y EPS Growth —

This Y EPS Growth (19.90%)

Next Y EPS Growth 17.01%

Next Y revenue growth —

Next 5Y EPS Growth (26.03%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

P/B against its own 10 years 63.62%

10-year low 10-year high

EV/Sales against its own 10 years 1.01%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	204	260	209	167
Receivables	21	21	22	13
Inventory	—	—	—	—
Other	8	6	5	5
	233	287	236	184

	2023	2024	2025	Q'26
Payables	19	19	17	18
ST’ Debt	5	16	10	8
Other	12	11	14	12
	155	166	146	135

Compound Annual Growth %

	10y	5y	3y
Sales	3.60%	(0.70%)	45.72%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(12.63%)	(24.47%)	(15.53%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	7	—	—	—
’25	12	18	37	12	80
’24	6	10	18	15	49
’23	4	2	2	2	9
’22	4	3	2	17	26
’21	28	15	11	(15)	39
’20	52	5	9	17	82

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(14)	—	—	—
’25	(17)	(10)	(2)	(10)	(39)
’24	(23)	52	(6)	0	23
’23	(28)	(19)	(17)	40	(25)
’22	(37)	(24)	(26)	(1)	(87)
’21	(41)	(12)	(30)	(21)	(105)
’20	1	(22)	(26)	(34)	(80)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(15)	—	—	—
’25	(18)	(11)	(4)	(11)	(43)
’24	(24)	51	(7)	(2)	19
’23	(29)	(21)	(17)	39	(26)
’22	(37)	(25)	(27)	(1)	(90)
’21	(49)	(18)	(36)	(21)	(123)
’20	(6)	(36)	(32)	(52)	(126)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	(0.22)	—	—	—
’25	(0.18)	(0.24)	0.01	(0.26)	(0.67)
’24	0.05	(0.28)	(0.23)	0.05	(0.41)
’23	(0.58)	(0.19)	(0.31)	(0.64)	(1.77)
’22	(0.70)	(0.42)	(0.63)	(0.59)	(2.33)
’21	(0.28)	(0.88)	(0.82)	(0.55)	(2.55)
’20	0.47	(0.76)	(0.71)	(0.95)	(1.91)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	16.09	17.25	15.44	9.50	7.32	7.80	1.83	0.96	1.41	1.10	Analyst estimates 2026–2028 Powerpack
	High	34.99	35.07	38.85	20.84	33.59	34.71	8.82	4.04	3.38	5.48
People
People	Employees	122	135	171	264	281	294	237	221	222	229
	Revenue/emp, $m	0.46	0.25	0.13	0.09	0.29	0.13	0.11	0.04	0.22	0.35
Income, $m
Income, $m	Revenue	56	34	21	23	82	39	26	9	49	80
	Gross margin, %	96.85	92.23	87.22	50.45	56.01	95.22	93.11	91.98	100.00	100.00
	EBT	(67)	(104)	(88)	(115)	(97)	(97)	(99)	(116)	(37)	(68)
	EBT margin, %	(119.15)	(307.53)	(412.15)	(501.14)	(118.22)	(250.66)	(383.29)	(1,266.89)	(74.69)	(85.46)
	Net income	(67)	(104)	(88)	(115)	(97)	(97)	(99)	(117)	(37)	(68)
	Depreciation	2	3	2	7	10	14	18	19	20	20
Per share, $
Per share, $	Revenue	1.60	0.94	0.53	0.54	1.94	0.86	0.56	0.16	0.54	0.79
	Earnings	(1.90)	(2.78)	(1.93)	(2.41)	(1.91)	(2.55)	(2.33)	(1.77)	(0.41)	(0.67)
	Cash flow	(0.93)	(1.47)	(1.67)	(1.63)	(1.89)	(2.33)	(1.92)	(0.43)	0.25	(0.39)
	Capex	(0.40)	0.13	(0.09)	(0.30)	(1.09)	(0.41)	(0.05)	(0.02)	(0.04)	(0.04)
	Free cash flow	(1.32)	(1.34)	(1.76)	(1.92)	(2.98)	(2.75)	(1.97)	(0.45)	0.21	(0.43)
	Book value	7.79	7.96	11.04	8.38	7.27	5.28	2.77	1.49	1.45	0.76
	Shares, m	35	36	41	42	43	45	46	57	91	100
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	11.32	31.85	31.68	31.61	13.95	9.43	4.02	19.04	3.31	6.10
	P/B	2.33	3.78	1.51	2.04	3.72	1.54	0.82	2.07	1.24	6.39
	EV/Sales	6.20	23.05	10.65	17.98	11.13	5.19	1.22	2.79	(0.62)	4.54
	EV/FCF	(7.49)	(16.25)	(3.18)	(5.06)	(7.25)	(1.63)	(0.35)	(0.93)	(1.58)	(8.18)
Cash, $m
Cash, $m	Operating cash flow	(33)	(52)	(68)	(69)	(80)	(105)	(87)	(25)	23	(39)
	Capex	(14)	5	(4)	(13)	(46)	(19)	(2)	(1)	(4)	(4)
	Free cash flow	(47)	(48)	(72)	(82)	(126)	(123)	(90)	(26)	19	(43)
Balance, $m
Balance, $m	Working capital	256	278	441	329	263	176	81	78	121	90
	Total debt	2	0	1	48	36	22	26	54	67	84
	Net debt	(289)	(297)	(451)	(313)	(233)	(164)	(72)	(149)	(193)	(124)
	Shareholders’ equity	275	284	450	355	309	236	126	85	131	76
Returns, %
Returns, %	ROA	(18.94)	(29.92)	(18.88)	(21.09)	(17.31)	(26.82)	(33.00)	(33.94)	(10.24)	(19.09)
	ROIC	0.00	0.00	0.00	(182.91)	(70.08)	(88.93)	(104.04)	0.00	0.00	0.00
	ROE	(23.71)	(35.57)	(21.43)	(25.34)	(24.41)	(41.88)	(58.57)	(95.96)	(34.08)	(65.33)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AARD Aardvark Therapeutics, Inc.	$84.5M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CRBP Corbus Pharmaceuticals Holdings, Inc.	$83.8M	— (loss-making)	— (loss-making)	−92.09% (below 0%: shrinking)	n/m	−78.52% (below 0%: shrinking)	0.00%	0.00%	Compare
EQ Equillium, Inc.	$83.7M	— (loss-making)	— (loss-making)	−52.32% (below 0%: shrinking)	n/m	−38.67% (below 0%: shrinking)	100.00%	0.00%	Compare
NMRA Neumora Therapeutics, Inc.	$80.2M	— (loss-making)	—	—	n/m	+24.45% (above 0%: growing)	0.00%	0.00%	Compare
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
PTHS Pelthos Therapeutics Inc.	$77.6M	— (loss-making)	— (loss-making)	—	n/m	−1,614.99% (below 0%: shrinking)	76.86%	(111.02%)	Compare
TELO Telomir Pharmaceuticals, Inc.	$77.3M	— (loss-making)	—	—	n/m	−45.34% (below 0%: shrinking)	—	0.00%	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
Median of peers	$79.1M	—	—	−41.02%	—	−61.24%	20.79%	0.00%

All 614 Biotechnology stocks →

Cellectis S.A. (CLLS) key facts

Strength: Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024.
Cellectis S.A. (CLLS) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, CLLS traded at $1.04, a market capitalization of $79.9 million.
Return on equity was −65.3% and debt-to-equity 1.79.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −0.03 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.